A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

Name: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
Creator: Vivli
Published: 2025-06-01 01:05:32
License: 暂无描述

DataCite Commons2025-06-01 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00009888/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in patients having pain symptoms associated with uterine fibroids.

提供机构：

Vivli

创建时间：

2024-03-14